JAMDA
Volume 10, Issue 1 , Pages 21-27 , January 2009

A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia

Data from this manuscript were presented as a poster at the American Psychiatric Association Annual Meeting in June 2007.

  • Stephen A. Rappaport, MD

      Affiliations

    • Agewell® Health, Indianapolis, IN
    • Corresponding Author InformationAddress correspondence to Stephen A. Rappaport, MD, Agewell® Health, 9292 North Meridian Street, Suite 107, Indianapolis, IN 46260
  • ,
  • Ronald N. Marcus, MD

      Affiliations

    • Bristol-Myers Squibb, Wallingford, CT
  • ,
  • George Manos, PhD

      Affiliations

    • Bristol-Myers Squibb, Wallingford, CT
  • ,
  • Robert D. McQuade, PhD

      Affiliations

    • Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ
  • ,
  • Dan A. Oren, MD

      Affiliations

    • Bristol-Myers Squibb, Wallingford, CT

  • Image Result

    Mean change in Simpson−Angus Scale Total score from baseline during intramuscular treatment. The Simpson−Angus Scale is a 10-item scale rated from 1 (normal) to 5 (worst), with a negative change on th

    Mean change in Simpson−Angus Scale Total score from baseline during intramuscular treatment. The Simpson−Angus Scale is a 10-item scale rated from 1 (normal) to 5 (worst), with a negative change on the Total score (scale 10–50) indicating a reduction in extrapyramidal symptoms.

  • Image Result
    Efficacy outcomes during intramuscular treatment. (A) Mean change in Positive and Negative Syndrome Scale Excited Component (PEC) score from baseline, (B) mean Clinical Global Impression–Improvement (

    Efficacy outcomes during intramuscular treatment. (A) Mean change in Positive and Negative Syndrome Scale Excited Component (PEC) score from baseline, (B) mean Clinical Global Impression–Improvement (CGI-I) score, (C) mean change in Agitation–Calmness Evaluation Scale (ACES) score from baseline (last observation carried forward data set). The PEC score consists of 5 PANSS items (hostility, lack of cooperation, excitement, poor impulse control, tension), each rated on a scale of 1 (absent) to 7 (extreme). A negative change from baseline in the PEC score (scale 5–35) signifies improvement. The CGI-I score is measured on a scale from 1 (very much improved) to 7 (very much worse), where a lower score signifies greater improvement. The ACES score is assessed on a scale of 1 (marked agitation) to 9 (unarousable); a score of 4 indicates normal; a positive change from baseline signifies improvement.

 This study was supported by Bristol-Myers Squibb (Princeton, NJ) and Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). Editorial support for the preparation of this manuscript was provided by Ogilvy Healthworld Medical Education; funding was provided by Bristol-Myers Squibb.

PII: S1525-8610(08)00253-3

doi: 10.1016/j.jamda.2008.06.006

JAMDA
Volume 10, Issue 1 , Pages 21-27 , January 2009